Early Palliative Care in Non–Small-Cell Lung Cancer

Authors:

Abstract
The surprising and encouraging study by Temel and colleagues (Aug. 19 issue)1 suggests that the early introduction of palliative care prolongs survival among patients with metastatic non-small-cell lung cancer. However, two essential points regarding patient demographic characteristics were not reported. First, there were no data regarding the regimens and number of chemotherapy cycles in each group. Could the patients assigned to early palliative care undergo more chemotherapy? Second, the authors did not describe whether the patients assigned to early palliative care, as compared with the patients assigned to standard care, had better performance status after intervention. The use of chemotherapy and performance status are inextricably linked with survival in metastatic non–small-cell lung cancer.2,3 We would like to know whether the early palliative care itself resulted in longer survival through improvements in the quality of life and mood or whether the better performance status restored with early palliative care made it possible to receive additional chemotherapy at an appropriate time that might confer a survival benefit.

This publication has 10 references indexed in Scilit: